BETRUVO
DEAD

Serial Number

98771029

Owner

SAREPTA THERAPEUTICS, INC.

Attorney

Maury M. Tepper, III

Filing Date

Sep 26, 2024

Add to watchlist:

No watchlists yet
View on USPTO

BETRUVO Trademark

Serial Number: 98771029

BETRUVO is a trademark filed by SAREPTA THERAPEUTICS, INC. on September 26, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

SAREPTA THERAPEUTICS, INC. (109 trademarks)

215 FIRST STREET, SUITE 7
CAMBRIDGE, MA 02142

Entity Type: 03

Trademark Details

Filing Date

September 26, 2024

Registration Date

Not Registered

Published for Opposition

August 12, 2025

Goods & Services

Medical training and teaching

Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies in the nature of pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases

Medical services; providing health information

Filing History

ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Aug 26, 2025 MAB5
ABANDONMENT - AFTER PUBLICATION
Aug 26, 2025 ABN5
TEAS EXPRESS ABANDONMENT RECEIVED
Aug 25, 2025 EXAR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 12, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 12, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 6, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 8, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 8, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 8, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 8, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 8, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 7, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 7, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 7, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 8, 2025 GNRN
NON-FINAL ACTION E-MAILED
Apr 8, 2025 GNRT
NON-FINAL ACTION WRITTEN
Apr 8, 2025 CNRT
ASSIGNED TO EXAMINER
Apr 2, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 1, 2025 NWOS
NEW APPLICATION ENTERED
Sep 26, 2024 NWAP